Skip to main content

Table 3 Characteristics of patients with non-small cell lung cancer treated with docetaxel with or without prior ICI treatment

From: Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy

 

Patients, No. (%)

Full study population

Propensity score-matched cohort

Post-ICI

ICI-naïve

P-value

Post-ICI

ICI-naïve

P-value

(N = 28)

(N = 55)

(N = 23)

(N = 23)

Age, median (range), y

67 (43–79)

65 (33–83)

.18

66 (43–79)

65 (44–83)

.82

Sex

      

 Male

22 (78.6)

40 (72.7)

.61

17 (73.9)

17 (73.9)

>.99

 Female

6 (21.4)

15 (27.3)

 

6 (26.1)

6 (26.1)

 

ECOG-PS

      

 0 or 1

23 (82.1)

46 (72.1)

>.99

19 (82.6)

18 (78.3)

>.99

 ≥2

5 (17.8)

9 (27.9)

 

4 (17.4)

5 (21.7)

 

Smoking status

      

 Never

4 (14.3)

13 (23.6)

.39

3 (13.0)

7 (30.4)

.16

 Current or former

24 (85.7)

40 (72.7)

 

20 (87.0)

15 (65.2)

 

 Unknown

0 (0)

2 (3.6)

  

1 (4.3)

 

Histological subtype

      

 Adenocarcinoma

21 (75.0)

37 (67.3)

.82

16 (69.6)

17 (73.9)

>.99

 Squamous cell carcinoma

4 (14.3)

11 (20.0)

 

4 (17.4)

3 (13.0)

 

 Othera

3 (10.7)

7 (12.7)

 

3 (13.0)

3 (13.0)

 

Comorbidity

      

 Hypertension

12 (42.9)

17 (30.9)

.33

9 (39.1)

9 (39.1)

>.99

 Diabetes mellitus

7 (25.0)

8 (14.5)

.36

5 (21.7)

6 (26.1)

>.99

 COPD

3 (10.7)

6 (10.9)

>.99

3 (13.0)

3 (13.0)

>.99

 Pulmonary emphysema

13 (46.4)

23 (41.8)

.81

11 (47.8)

9 (39.1)

.76

 Pleural fluid

16 (57.2)

19 (34.5)

.06

14 (60.9)

10 (43.5)

.37

 ILD

2 (7.1)

5 (9.1)

>.99

2 (8.7)

3 (13.0)

>.99

 Radiation pneumonitis

3 (10.7)

5 (9.1)

>.99

3 (13.0)

1 (4.3)

.61

 Cardiovascular disease

2 (7.1)

10 (18.2)

.32

2 (8.7)

3 (13.0)

>.99

 Renal disorder

0 (0)

2 (3.6)

.54

0 (0)

2 (8.7)

.48

Stage

      

 III

5 (17.2)

13 (23.6)

.58

5 (21.7)

4 (17.4)

.43

 IV

20 (69.0)

38 (69.1)

 

17 (73.9)

15 (65.2)

 

 Recurrence

3 (10.7)

4 (7.3)

 

1 (4.3)

4 (17.4)

 

History of prior thoracic radiotherapy

6 (21.4)

10 (18.2)

.77

6 (26.1)

2 (8.7)

.24

irAEs in prior ICI therapy

      

 ICI-induced ILD

2 (7.1)

NA

 

1 (4.3)

NA

 

 Others

12 (42.9)

  

10 (43.5)

  

Docetaxel treatment

      

 Monotherapy

10 (35.7)

29 (52.7)

.004

10 (43.5)

10 (43.5)

 >.99

 With VEGF/VEGF-R inhibitorsb

17 (60.7)

14 (25.5)

 

12 (52.2)

12 (52.2)

 

 With cisplatin

1 (3.6)

12 (21.8)

 

1 (4.3)

1 (4.3)

 

Treatment line

      

 ≤3rd

25 (89.3)

48 (87.3)

 >.99

21 (91.3)

18 (78.3)

.41

 ≥4th

3 (10.7)

7 (12.7)

 

2 (8.7)

5 (21.7)

 

Duration of docetaxel therapy, median (range), m

2.0 (0.5–10.1)

2.6 (0.5–22.1)

.95

2.1 (0.5–10.1)

1.6 (0.5–22.1)

.86

Total cycle of docetaxel, median (range)

3 (1–14)

4 (1–31)

.91

3 (1–13)

3 (1–31)

.93

  1. aOther histology includes NSCLC not otherwise specified, large cell neuroendocrine carcinoma, and adenosquamous carcinoma
  2. bVEGF/VEGF-R inhibitors include ramucirumab (full study population, N = 17 [post-ICI] vs N = 5 [ICI-naive]; propensity score-matched cohort, N = 12 [post-ICI] vs N = 5 [ICI-naive]) and bevacizumab (full study population, N = 0 [post-ICI] vs N = 9 [ICI-naive]; propensity score-matched cohort, N = 0 [post-ICI] vs N = 7 [ICI-naive])
  3. COPD: chronic obstructive pulmonary disease; ECOG: Eastern Cooperative Oncology Group; ICI: immune checkpoint inhibitor; ILD: interstitial lung disease; irAEs: immune-related adverse events; NA: not applicable; PS: performance status; VEGF: vascular endothelial growth factor; VEGF-R: vascular endothelial growth factor-receptor
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us